Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on November 4, 2020, reporting its financial results for the third quarter of 2020, which were announced via a press release on November 5, 2020. The filing primarily serves to furnish this press release and supplemental information from the company's website. Investors should refer to Exhibit 99.1 for the detailed earnings press release and Exhibit 99.2 for additional financial data. While this 8-K does not contain extensive new operational details or forward-looking statements beyond what was presented in the earnings release, it is the official channel for disseminating these results. Investors interested in BMY's performance for Q3 2020 will need to consult the furnished exhibits to understand revenue, earnings, and any management commentary regarding the company's financial condition and outlook.
Key Highlights
- 1BMY announced its third quarter 2020 financial results on November 5, 2020.
- 2The 8-K filing primarily furnishes the company's earnings press release (Exhibit 99.1).
- 3Supplemental financial information from the company's website is also included as Exhibit 99.2.
- 4Investors are directed to the furnished exhibits for detailed financial performance data.
- 5The filing date of the 8-K is November 4, 2020, with the event date being November 5, 2020 (related to the earnings announcement).
- 6This report serves as the official SEC filing for the Q3 2020 earnings announcement.